[go: up one dir, main page]

WO2007068841A3 - Utilisation d'une composition à base de trétinoine, d'hydroquinone et d'acétonide de fluocinolone, en accompagnement d'un peeling chimique - Google Patents

Utilisation d'une composition à base de trétinoine, d'hydroquinone et d'acétonide de fluocinolone, en accompagnement d'un peeling chimique Download PDF

Info

Publication number
WO2007068841A3
WO2007068841A3 PCT/FR2006/051290 FR2006051290W WO2007068841A3 WO 2007068841 A3 WO2007068841 A3 WO 2007068841A3 FR 2006051290 W FR2006051290 W FR 2006051290W WO 2007068841 A3 WO2007068841 A3 WO 2007068841A3
Authority
WO
WIPO (PCT)
Prior art keywords
tretinoin
hydroquinone
accompanied
fluocinolone acetonide
composition based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2006/051290
Other languages
English (en)
Other versions
WO2007068841A2 (fr
Inventor
Isabelle Pelisson
Andre Jomard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma SA
Original Assignee
Galderma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma SA filed Critical Galderma SA
Publication of WO2007068841A2 publication Critical patent/WO2007068841A2/fr
Publication of WO2007068841A3 publication Critical patent/WO2007068841A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention se rapporte à l'utilisation d'une association d'hydroquinone, de trétinoïne et d'acétonide de fluocinolone pour préparer une composition destinée à prévenir et/ou diminuer les désordres hyperpigmentaires associés à l'application d'un peeling chimique de la peau.
PCT/FR2006/051290 2005-12-14 2006-12-06 Utilisation d'une composition à base de trétinoine, d'hydroquinone et d'acétonide de fluocinolone, en accompagnement d'un peeling chimique Ceased WO2007068841A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0512677 2005-12-14
FR0512677A FR2894479A1 (fr) 2005-12-14 2005-12-14 Utilisation d'une composition a base de tretinoine, d'hydroquinone et d'acetonide de fluocinolone, en accompagnement d'un peeling chimique

Publications (2)

Publication Number Publication Date
WO2007068841A2 WO2007068841A2 (fr) 2007-06-21
WO2007068841A3 true WO2007068841A3 (fr) 2007-08-02

Family

ID=36481466

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/051290 Ceased WO2007068841A2 (fr) 2005-12-14 2006-12-06 Utilisation d'une composition à base de trétinoine, d'hydroquinone et d'acétonide de fluocinolone, en accompagnement d'un peeling chimique

Country Status (2)

Country Link
FR (1) FR2894479A1 (fr)
WO (1) WO2007068841A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037201A2 (fr) * 2002-10-25 2004-05-06 Hill Dermaceuticals, Inc. Composition de soin pour la peau a application topique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037201A2 (fr) * 2002-10-25 2004-05-06 Hill Dermaceuticals, Inc. Composition de soin pour la peau a application topique

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Dermatology discussions - Interview with Dr Sungbin Im", PIGMENT MATTERS - AUTUMN 2005 / PUBLISHED BY MEDSENSE LTD, ON BEHALF OF GALDERMA INTERNATIONAL., no. 6, 4 January 2006 (2006-01-04), pages 11 - 12, XP002432728, Retrieved from the Internet <URL:HTTP://WWW.PIGMENTARYDISORDERSACADEMY.ORG/PIGMATTERS_Autumn_2005.PDF> *
"Tri-LumaTM cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%)", PRESCRIBING INFORMATIONS, 6 April 2004 (2004-04-06), Galderma Laboratoires, L.P., Fort Worth, TX 76177, USA, XP002403787, Retrieved from the Internet <URL:http://web.archive.org/web/20040406072345/triluma.com/prescribing_info.pdf> [retrieved on 20061017] *
BAUMANN L: "Efficacy and safety of triple-combination cream versus vehicle cream in the treatment of patients with postinflammatory hyperpigmentation", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, C.V. MOSBY, ST. LOUIS, MO, US, P2606, vol. 52, no. 3, March 2005 (2005-03-01), pages P168, XP004788713, ISSN: 0190-9622 *
BETH GILBERT: "TriLuma combination effective for PIH", DERMATOLOGY TIMES, ADVANSTAR COMMUNICATIONS, 1 September 2005 (2005-09-01), CLEVELAND, OH, US, XP002403792, ISSN: 0196-6197, Retrieved from the Internet <URL:http://www.dermatologytimes.com/dermatologytimes/article/articleDetail.jsp?id=178457> [retrieved on 20061017] *
COOK-BOLDEN F ET AL: "THE USE OF A TRIPLE-DRUG COMBINATION PRODUCT AND PROCEDURES FOR THE TREATMENT OF HYPERPIGMENTARY DISORDERS", COSMETIC DERMATOLOGY, KNOLLS PUB. GROUP, CEDAR KNOLLS, NJ, US, vol. 18, no. 8, August 2005 (2005-08-01), pages 589 - 594, XP009066078, ISSN: 1041-3766 *
GOODHEART H P: "Hyperpigmentation disorders . MELASMA, POSTINFLAMMATORY HYPERPIGMENTATION, ACANTHOSIS NIGRICANS", PRIMARY CARE, SAUNDERS, LONDON, GB, vol. 2, no. 12, December 1999 (1999-12-01), pages 923 - 924,929, XP002251799, ISSN: 0095-4543 *
GRIMES P E: "Agents for ethnic skin peeling", DERMATOLOGIC THERAPY 2000 DENMARK, vol. 13, no. 2, 2000, pages 159 - 164, XP002403786, ISSN: 1396-0296 *
GRIMES P,: "Treatment of pigmentary disorders in racial ethnic groups: Choosing your weapon", PIGMENT MATTERS - SUMMER 2004 / PUBLISHED BY MEDSENSE LTD, ON BEHALF OF GALDERMA INTERNATIONAL., no. 2, 6 July 2004 (2004-07-06), pages 1 - 3, XP002432653, Retrieved from the Internet <URL:HTTP://WWW.PIGMENTARYDISORDERSACADEMY.ORG/PIGMATTERS_SUMMER.PDF> *
H. M. TOROK: "The resurgence of chemical peels", US DERMATOLOGY REVIEW 2006, TOUCH BRIEFINGS, vol. 1, December 2005 (2005-12-01), pages 88 - 91, XP001247928 *

Also Published As

Publication number Publication date
WO2007068841A2 (fr) 2007-06-21
FR2894479A1 (fr) 2007-06-15

Similar Documents

Publication Publication Date Title
WO2007014278A3 (fr) Reduction de lymphocytes b au moyen de molecules de liaison specifique de cd37 et specifique de cd20
WO2008054676A3 (fr) Dispositifs médicaux et méthodes d&#39;utilisation correspondantes
WO2007073484A3 (fr) Procedes et systemes de conduite d’operations de recherche
WO2007092850A3 (fr) Pulvérisateur puissant
AU2006266167A8 (en) Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation
EP1759343A4 (fr) Procede facilitant la distribution de publicites presentant differents traitements et/ou differentes caracteristiques, telles que les publicites textuelles et les publicites en images
WO2008042216A3 (fr) PROCÉDÉS, matÉriel et compositions pour gÉNÉrer de nouveaux follicules pileux et faire pousser les cheveux
WO2006116348A3 (fr) Compositions destinees a des dispositifs medicaux contenant des combinaisons d&#39;agents dans des volumes controles
WO2009042114A3 (fr) Dérivés de phénazine et leurs utilisations
WO2007084857A3 (fr) Procédés et compositions de traitement de troubles prolifératifs cellulaires
WO2009029883A3 (fr) Procédés et compositions permettant de moduler les lymphocytes t
WO2007095258A3 (fr) compositions comprenant un rhamnolipide et leurs procedes d&#39;utilisation
EP2087880A3 (fr) Compositions, kits et régimes de traitement de la peau, et plus spécialement du décolleté
WO2007061939A3 (fr) Dérivés de métabolites de l&#39;inhibiteur de hdac fk228
GEP20115245B (en) Solid preparation
WO2009013133A3 (fr) Profilé présentant au moins une section à profil creux
WO2006099232A3 (fr) Lingette antimicrobienne pour animaux domestiques et procedes associes
WO2007076159A3 (fr) Bromhydrate de darifenacine pur sensiblement exempt de darifenacine oxydee, sels de celui-ci, et procedes de preparation de ceux-ci
WO2007050348A3 (fr) Inhibiteurs du canal potassique
WO2008006883A3 (fr) Benzopyranopyrazoles
WO2009017719A8 (fr) Modulateurs du récepteur ccr9 et leurs procédés d&#39;utilisation
WO2009101199A3 (fr) Traitement de l&#39;acné vulgaire, de la rosacée et du rhinophyme
WO2006099219A3 (fr) Agrafes chirurgicales absorbables
WO2006098998A3 (fr) Procedes et compositions de modulation de l&#39;integrite vasculaire
WO2006136932A8 (fr) Charniere de branche de monture de lunettes bloquant le verre

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06842101

Country of ref document: EP

Kind code of ref document: A2